|Methods for identification and confirmation of targeted subgroups in clinical trials: a systematic review|
T Ondra, A Dmitrienko, T Friede, A Graf, F Miller, N Stallard, M Posch
Journal of biopharmaceutical statistics 26 (1), 99-119, 2016
|A simulation study to compare new adaptive dose–ranging designs|
V Dragalin, B Bornkamp, F Bretz, F Miller, SK Padmanabhan, N Patel, ...
Statistics in Biopharmaceutical Research 2 (4), 487-512, 2010
|Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients|
J Peuskens, J Trivedi, S Malyarov, M Brecher, O Svensson, F Miller, ...
Psychiatry (Edgmont) 4 (11), 34, 2007
|A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or …|
JW Newcomer, RE Ratner, JW Eriksson, R Emsley, D Meulien, F Miller, ...
Journal of Clinical Psychiatry; Journal of Clinical Psychiatry, 2009
|Optimal designs for estimating the interesting part of a dose-effect curve|
F Miller, O Guilbaud, H Dette
Journal of Biopharmaceutical Statistics 17 (6), 1097-1115, 2007
|Psychometric evaluation of ADAS‐C og and NTB for measuring drug response|
A Karin, K Hannesdottir, J Jaeger, P Annas, M Segerdahl, P Karlsson, ...
Acta Neurologica Scandinavica 129 (2), 114-122, 2014
|Experiences with an adaptive design for a dose-finding study in patients with osteoarthritis|
F Miller, M Björnsson, O Svensson, R Karlsten
Contemporary clinical trials 37 (2), 189-199, 2014
|Variance estimation in clinical studies with interim sample size reestimation|
Biometrics 61 (2), 355-361, 2005
|Adaptive and model-based dose-ranging trials: quantitative evaluation and recommendations. White paper of the PhRMA working group on adaptive dose-ranging studies|
J Pinheiro, F Sax, Z Antonijevic, B Bornkamp, F Bretz, C Chuang-Stein, ...
Statistics in Biopharmaceutical Research 2 (4), 435-454, 2010
|Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia|
HJ Möller, S Johnson, T Mateva, M Brecher, O Svensson, F Miller, ...
International clinical psychopharmacology 23 (2), 95, 2008
|Adaptive two-stage test procedures to find the best treatment in clinical trials|
W Bischoff, F Miller
Biometrika 92 (1), 197-212, 2005
|Asymptotically optimal tests and optimal designs for testing the mean in regression models with applications to change-point problems|
W Bischoff, F Miller
Annals of the Institute of Statistical Mathematics 52 (4), 658-679, 2000
|Exact asymptotics for boundary crossings of the Brownian bridge with trend with application to the Kolmogorov test|
W Bischoff, E Hashorva, J Hüsler, F Miller
Annals of the Institute of Statistical Mathematics 55 (4), 849-864, 2003
|Asymptotics of a boundary crossing probability of a Brownian bridge with general trend|
W Bischoff, F Miller, E Hashorva, J Hüsler
Methodology and Computing in Applied Probability 5 (3), 271-287, 2003
|Determination of the optimal sample size for a clinical trial accounting for the population size|
N Stallard, F Miller, S Day, SW Hee, J Madan, S Zohar, M Posch
Biometrical Journal 59 (4), 609-625, 2017
|Optimal designs which are efficient for lack of fit tests|
W Bischoff, F Miller
Annals of statistics 34 (4), 2015-2025, 2006
|Decision-theoretic designs for small trials and pilot studies: a review|
SW Hee, T Hamborg, S Day, J Madan, F Miller, M Posch, S Zohar, ...
Statistical methods in medical research 25 (3), 1022-1038, 2016
|Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials. gov|
SW Hee, A Willis, CT Smith, S Day, F Miller, J Madan, M Posch, S Zohar, ...
Orphanet journal of rare diseases 12 (1), 1-20, 2017
|A note on change point estimation in dose–response trials|
T Friede, F Miller, W Bischoff, M Kieser
Computational statistics & data analysis 37 (2), 219-232, 2001
|Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo …|
J Peuskens, JK Trivedi, M Brecher, F Miller
International clinical psychopharmacology 25 (3), 183, 2010